We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.84%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.13B
AUM Growth
-$201M
Cap. Flow
-$504M
Cap. Flow %
-9.84%
Top 10 Hldgs %
88.73%
Holding
94
New
14
Increased
25
Reduced
6
Closed
34

Top Buys

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$30.9M
2
CELG
Celgene Corp
CELG
+$26.8M
3
BAC icon
Bank of America
BAC
+$13.5M
4
APTV icon
Aptiv
APTV
+$12M
5
C icon
Citigroup
C
+$10.4M

Top Sells

Rank Stock Value
1
LNKD
LinkedIn Corporation
LNKD
+$22.5M
2
YUM icon
Yum! Brands
YUM
+$21.9M
3
MBLY
Mobileye N.V.
MBLY
+$14.8M
4
GM icon
General Motors
GM
+$13.6M
5
V icon
Visa
V
+$13.6M

Sector Composition

Rank Sector Weight
1 Consumer Staples 57.56%
2 Healthcare 18.9%
3 Consumer Discretionary 9.33%
4 Financials 2.31%
5 Industrials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CCXI
51
DELISTED
ChemoCentryx, Inc.
CCXI
$2.24M 0.04%
900,000
DMTX
52
DELISTED
Dimension Therapeutics, Inc
DMTX
$2.15M 0.04%
275,000
+100,000
+57% +$788K
GLPI icon
53
Gaming and Leisure Properties
GLPI
$13B
$2.1M 0.04%
+70,000
New +$1.9M
AGEN
54
CALL
Agenus
AGEN
$276M
$2.08M 0.04%
+25,475
New +$1.72M
IBRX icon
55
ImmunityBio
IBRX
$7.15B
$1.85M 0.04%
225,000
RGNX icon
56
Regenxbio
RGNX
$615M
$1.73M 0.03%
160,000
PARN
57
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$1.06M 0.02%
500,000
IMDX
58
Insight Molecular Diagnostics
IMDX
$140M
$296K 0.01%
+3,205
New +$284K
CERE
59
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$225K ﹤0.01%
1,024,020
CLCD
60
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$35K ﹤0.01%
5,575
BABA icon
61
CALL
Alibaba
BABA
$276B
-300,000
Closed -$24.4M
BLUE
62
CALL
DELISTED
bluebird bio
BLUE
-3,860
Closed -$3.21M
BMRN icon
63
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
-100,000
Closed -$10.5M
BMY icon
64
CALL
Bristol-Myers Squibb
BMY
$129B
-500,000
Closed -$34.4M
GE icon
65
CALL
GE Aerospace
GE
$364B
-104,331
Closed -$15.6M
GILD icon
66
CALL
Gilead Sciences
GILD
$165B
-300,000
Closed -$30.4M
GM icon
67
CALL
General Motors
GM
$80.9B
-1,000,000
Closed -$34M
GM icon
68
General Motors
GM
$80.9B
-400,000
Closed -$13.6M
IBB icon
69
CALL
iShares Biotechnology ETF
IBB
$9.45B
-300,000
Closed -$33.8M
INCY icon
70
CALL
Incyte
INCY
$25.4B
-50,000
Closed -$5.42M
IONS icon
71
CALL
Ionis Pharmaceuticals
IONS
$8.93B
-100,000
Closed -$6.19M
HAPN
72
CALL
Happen Inc
HAPN
$2.14B
-65,000
Closed -$3.59M
MRK icon
73
CALL
Merck
MRK
$322B
-524,000
Closed -$26.4M
MS icon
74
CALL
Morgan Stanley
MS
$320B
-1,000,000
Closed -$31.8M
MU icon
75
CALL
Micron Technology
MU
$835B
-1,000,000
Closed -$14.2M

Similar funds

Artal Group's Q1 2016 Portfolio in Review

As of Q1 2016, Artal Group held 94 positions worth $5.13B, down 3.8% from $5.33B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Artal Group withdrew a net $504M in Q1 2016, closing 34 positions and reducing 6 holdings. Its most notable exit was LinkedIn Corporation, an estimated $22.5M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 58% of assets, up from 40% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Goldman Sachs worth $31.4M.

  • Artal Group's largest Q1 2016 buy was Goldman Sachs: 200,000 shares worth $31.4M.
  • Artal Group added most to Celgene Corp in Q1 2016, an estimated $26.8M increase.
  • Artal Group's biggest Q1 2016 reduction was Mastercard, cutting an estimated $8.84M.
  • Artal Group fully exited LinkedIn Corporation in Q1 2016, selling an estimated $22.5M.
  • Artal Group's ten largest holdings make up 89% of its $5.13B portfolio in Q1 2016.
  • Artal Group opened 14 new positions and closed 34 in Q1 2016.
  • Artal Group's portfolio value fell 3.8% quarter-over-quarter to $5.13B.

Based on Artal Group's 13F filing for Q1 2016, filed 12 May 2016.